Biosimilar Glargine Insulin: Implications for Prescribers and Patients

被引：1
|
作者：
Pereira, Katherine [1 ,2 ]
机构：
[1] Duke Univ, Sch Nursing Durham, Durham, NC 27708 USA
[2] Duke Univ, Sch Nursing Durham, Doctor Nursing Practice Program, Div Endocrinol Metab & Nutr, Durham, NC 27708 USA
来源：
JNP-JOURNAL FOR NURSE PRACTITIONERS | 2017年 / 13卷 / 03期
关键词：
FOLLOW-ON-BIOLOGICS; COMPETITION;
D O I：
10.1016/j.nurpra.2016.11.022
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：236 / 237
页数：2
相关论文
共 50 条
  • [1] Hypersensitivity reaction to a biosimilar insulin glargine
    Garcia-Nares, Hector
    Leyva-Carmona, Maria Isabel
    Perez-Xochipa, Neftali
    Chiquete, Erwin
    JOURNAL OF DIABETES, 2015, 7 (02) : 155 - 157
  • [2] Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
    Tarigan, Tri Juli Edi
    Dwijayanti, Adisti
    Setyowati, Susie
    Louisa, Melva
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 107 - 116
  • [3] The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn
    Matli, Mark C.
    Wilson, Andrea B.
    Rappsilber, Leah M.
    Sheffield, Farron P.
    Farlow, Miranda L.
    Johnson, Jeremy L.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023, 17 (02): : 490 - 494
  • [4] Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market
    Levy, Joseph
    Chowdhury, Zahra M.
    Socal, Mariana P.
    Trujillo, Antonio J.
    JAMA INTERNAL MEDICINE, 2021, 181 (10) : 1405 - +
  • [5] Implementation of biosimilar uptake: a cost minimization study for insulin glargine
    Mehring, M.
    Heim, A.
    Peyrol, C.
    Pages, A.
    Bouothmani, A.
    McCambridge, C.
    Cestac, P.
    Mange, A. -S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 372 - 372
  • [6] Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment
    Christofides, Elena A.
    Stankiewicz, Andrzej
    Denham, Douglas
    Bellido, Diego
    Franek, Edward
    Nakhle, Samer
    Lukaszewicz, Monika
    Reed, John
    Cozar-Leon, Victoria
    Kosch, Christine
    Karas, Piotr
    Fitz-Patrick, David
    Handelsman, Yehuda
    Warren, Mark
    Hollander, Priscilla
    Huffman, David
    Raskin, Philip
    Oroszlan, Tamas
    Lillestol, Michael
    Ovalle, Fernando
    ENDOCRINE PRACTICE, 2024, 30 (09) : 810 - 816
  • [7] Efficacy, safety and immunogenicity of proposed biosimilar Gan & Lee insulin glargine versus EU-licensed insulin glargine in patients with type 2 diabetes
    Christofides, E. A.
    Xie, T.
    He, A.
    Li, L.
    Hao, C.
    Chen, W.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S415 - S416
  • [8] LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union
    Altman, Jean-Jacques
    Chevalier, Nicolas
    Delemer, Brigitte
    Travert, Florence
    Benabbad, Imane
    PRESSE MEDICALE, 2018, 47 (10): : 854 - 866
  • [9] Insulin Access Enhancement in India: Expert Views on Integrating Interchangeable Biosimilar Insulin Glargine
    Kumar, K. M. Prasanna
    Chowdhury, Subhankar
    Bantwal, Ganapathi
    Unnikrishnan, A. G.
    Kalra, Sanjay
    Aggarwal, Sameer
    Singh, Awadhesh Kumar
    Pandit, Kaushik
    Shukla, Rishi
    Vishwanathan, Vijay
    Khobragade, Kunal
    Sarda, Prashant S.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [10] The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine
    Fisher, Anat
    Kim, Jason D.
    Dormuth, Colin
    CLINICAL THERAPEUTICS, 2022, 44 (07) : 957 - +
12345